M28 Capital Management’s ProQR Therapeutics PRQR Stock Holding History

M28 Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Hold	599,793	–	–	2.37%	6
2026 Q1	$972K	Sell	599,793 -419,705	-41%	-$688K	1.81%	5
2025 Q4	$2.06M	Hold	1,019,498	–	–	1.5%	6
2025 Q3	$2.17M	Hold	1,019,498	–	–	3.19%	6
2025 Q2	$2.08M	Hold	1,019,498	–	–	3.55%	5
2025 Q1	$1.36M	Hold	1,019,498	–	–	1.86%	8
2024 Q4	$2.7M	Hold	1,019,498	–	–	2.65%	8
2024 Q3	$1.86M	Hold	1,019,498	–	–	2.04%	10
2024 Q2	$1.69M	Hold	1,019,498	–	–	2.19%	11
2024 Q1	$2.33M	Sell	1,019,498 -891,102	-47%	-$1.91M	1.73%	10
2023 Q4	$3.78M	Hold	1,910,600	–	–	3.13%	8
2023 Q3	$2.48M	Hold	1,910,600	–	–	2.85%	8
2023 Q2	$3.1M	Hold	1,910,600	–	–	4.09%	8
2023 Q1	$4.07M	Hold	1,910,600	–	–	4.6%	9
2022 Q4	$7.07M	Buy	1,910,600 +908,800	+91%	+$1.19M	6.74%	4
2022 Q3	$745K	Hold	1,001,800	–	–	0.78%	11
2022 Q2	$779K	Hold	1,001,800	–	–	0.87%	12
2022 Q1	$907K	Buy	+1,001,800	New	+$3.36M	0.83%	12

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

M28 Capital Management's PRQR Position: Q2 2026 in Review

M28 Capital Management held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 599,793 shares worth $1.12M. The position accounts for 2.37% of the portfolio, ranked #6.

M28 Capital Management first reported a position in PRQR in Q1 2022 and has held it in 18 quarters since. The position peaked at $7.07M in Q4 2022. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

M28 Capital Management held 599,793 shares of ProQR Therapeutics worth $1.12M as of Q2 2026.
M28 Capital Management left its ProQR Therapeutics share count unchanged in Q2 2026.
ProQR Therapeutics made up 2.37% of M28 Capital Management's portfolio in Q2 2026, its #6 holding.
M28 Capital Management first reported a position in ProQR Therapeutics in Q1 2022 and has held it in 18 quarters since.
M28 Capital Management's ProQR Therapeutics position peaked at $7.07M in Q4 2022.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on M28 Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.